VolFlashVOLFLASH
Sign inUpgrade to Pro
Relevance 38Low Regulation

US regulator rejects cancer drug invented in China in blow to Beijing’s biotech sector

Published2026-11-16 02:33 UTC
Updated2026-11-16 02:33 UTC
StatusNot analysed
Sourceft Wire
CoverageSingle source
Market relevance47
Source confidence60
Freshness35
Asset link confidence—No listed assets

Metrics metrics-v2.1 · Experimental; not used for ranking · Method

Regulation
Read source ↗
01

What happened

Reported fact

Summit’s ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US

The text and links above come from the source outlets. The transmission paths and judgement below are VolFlash inference based on those facts, not claims made by the outlets.

VolFlash analysisQueued

This event fell outside the real-time analysis window (published more than 6 hours ago), so no analysis was generated. Live events are analysed within a minute of publication.

07

Market reaction

Unavailable — no verified market reaction data.

VolFlash captures a market snapshot only within 5 minutes of a scheduled data release, with window, baseline and source attached. This event has no such capture, so there is no verified before/after price data — and we do not infer one.

08

Related events

Same topic / category
One email a day — don't miss the big ones

The 8 highest-severity events of the past 24h, with our read and source links. Unsubscribe anytime.

Published 2026-11-16 02:33:15 · Source ft · Automatically aggregated and analysed — verify against the original source.

Public information plus VolFlash reasoning. Not investment advice; no price targets.

All sources freshEvents 2m agoCollectors 2m agoCalendar 23m agoAnalysis 2m agoMarket data 45s agoDark pool 23m ago